Here are five updates to know on orthopedic medtech company Enovis, as reported by Becker’s so far in 2025:
- The company recorded $565 million in net sales during the second quarter of 2025, an increase of 7% compared to the same quarter in 2024.
- Enovis expanded its device portfolio with the addition of the Manafuse Bone Growth Stimulator.
- Enovis experienced a decline in its stock prices following the release of its first quarter financial results.
- Damien McDonald took over as the company’s new CEO in May.
- The company is planning to build a new manufacturing facility in Austin, Texas, expecting to add 162 in the area.
